Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-06-21 @ 9:00 PM
Study NCT ID:
NCT04300556
Status:
RECRUITING
Last Update Posted:
2025-11-14
First Post:
2020-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Sponsor:
Eisai Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumor | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lenvatinib | View |
| None | Farletuzumab ecteribulin | View |
| None | Neoplasms | View |
| None | Endometrial Neoplasms | View |
| None | Triple-Negative Breast Cancer | View |
| None | Endometrial Carcinoma | View |
| None | Carcinoma, Non-Small-Cell Lung | View |
| None | Adenocarcinoma | View |
| None | Ovarian Neoplasms | View |
| None | Folate Receptor Alpha (FRA) | View |